BioSpace News Archive

Sibylla Biotech announces the appointment of Dominique Bridon, Ph.D., as Executive Chairman of its Board of Directors.

Insulet Corporation announced plans to release its financial results for the third quarter of 2023 on November 2, 2023 after the close of the financial markets.

Merck, known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration has accepted for priority review a new Biologics License Application for sotatercept, Merck’s novel investigational activin signaling inhibitor, for the treatment of adult patients with pulmonary arterial hypertension .

Matinas BioPharma announces that Jerome D. Jabbour, Chief Executive Officer, will present a company overview and hold meetings with institutional investors at two upcoming investment conferences.

Bolt Biotherapeutics announced that the U.S. Food and Drug Administration granted Orphan Drug Designation for BDC-1001 for the treatment of gastric cancer, including gastroesophageal junction cancer.

Helius Medical Technologies, Inc. announced that its Portable Neuromodulation Stimulator system and mouthpiece have been assigned universal product code numbers by Wolters Kluwer Health – Medi-Span®.

Adial Pharmaceuticals, Inc. announced that on October 4, 2023, at 2:15 p.m. Eastern Time, it will be hosting a LinkedIn Live Key Opinion Leader webinar to discuss AUD, the current treatment landscape, and the need for non-abstinence-based therapeutics.

Applied Therapeutics, Inc. announced it will participate in a Symposium presentation, entitled Diabetic Cardiomyopathy : a severe complication of diabetes, at the 59th European Association for the Study of Diabetes Annual Meeting to take place October 2-6, 2023 in Hamburg, Germany and online.

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the acceptance of an abstract submitted to the American Society of Nephrology.

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, announced that Company management will participate in the following upcoming investor conferences in October.